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DATA, POLICIES AND CONFLICTS OF INTEREST IN RESEARCH 
JEREMY SUGARMAN, MD, MPH, MA* 
I.  INTRODUCTION 
In the wake of the death of Jesse Gelsinger in a gene transfer 
experiment at the University of Pennsylvania, substantial attention has 
focused on financial conflicts of interests (COIs) in research.1 Numerous 
groups have promulgated policies and guidance regarding these COIs, 
which typically involve a series of procedural steps to assess and manage 
financial interests in research.2 While a review of such policies is beyond the 
scope of this paper, they tend to share a common feature of considering 
disclosing financial interests to potential research participants. However, at 
the time many policies were crafted, little was known or specified about the 
process of disclosure, including who should disclose, what should be 
disclosed, when it should be disclosed, where it should be disclosed, how it 
should be disclosed, and what effects disclosure might have on the potential 
research participant and the research enterprise. For example, would 
disclosure affect willingness to participate in research? Would it affect trust? 
Nevertheless, the answers to such questions seem critical to understanding 
how such policies might be implemented, their potential effects, and their 
utility. The Conflict of Interest Notification Study (COINS) set out to provide 
systematic data about these and related issues. 
COINS was a multi-year project funded by the National Institutes of 
Health and included a multidisciplinary team of scholars based at Duke 
University, Johns Hopkins University, and Wake Forest University.3 At each 
stage of the project, COINS consulted an advisory panel, which consisted of 
individuals with expertise in clinical trials, conflicts of interest, ethics, and the 
 
* Berman Institute of Bioethics, Department of Medicine, and Department of Health Policy and 
Management, Johns Hopkins University, Baltimore, Maryland. 
 1.  See Robert Fretwell Wilson, The Death of Jesse Gelsinger: New Evidence of the 
Influence of Money and Prestige in Human Research, 36 AM. J.L. & MED. 295, 295-96 
(2010). 
 2.  See id. at 322. 
 3.  Press Release, Johns Hopkins Medicine, Disclosing Financial Conflicts of Interest to 
Research Participants May Not Be Enough (Aug. 26, 2009), available at http://www.hopkins 
medicine.org/news/media/releases/Disclosing_Financial_Conflicts_of_Interest_to_Research_ 
Participants_May_Not_Be_Enough. 
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law; the panel had representatives from academia and industry.4 In this 
paper, I review briefly what we learned over the course of the project and 
then discuss some barriers for gathering data about COIs that would 
enhance current understanding about these issues. 
II.  WHAT WE LEARNED 
COINS had several stages: 1) reviewing COI of policies; 2) obtaining 
stakeholder input; 3) developing model disclosure language and measures 
of trust; 4) evaluating the effects of disclosure; 5) considering the goals of 
disclosure; and 6) assessing COI management. I will discuss each of these 
in turn. 
A. COI Policies 
At the time of our review, the policies of nearly half of academic medical 
centers in the United States that had an Institutional Review Board (IRB) 
mentioned the possibility of disclosing financial conflicts of interest to 
potential research participants.5 In addition, more than half of those that 
mentioned disclosure included specific language that could be used.6 
However, there was substantial variability concerning the content of such 
disclosures.7 
We subsequently compared the results of our policy review with the 
findings from interviews with IRB and Conflict of Interest Committee (COIC) 
officials (described below).8 The interviews revealed a range of practices 
regarding the management of COIs that was broader than those suggested 
in written policies.9 Further, COI and IRB officials interpreted and 
understood policies regarding COI differently.10 
 
 4.  Kevin P. Weinfurt et al., Developing Model Language for Disclosing Financial 
Interests to Potential Clinical Research Participants, IRB: ETHICS & HUMAN RES., Jan.-Feb. 2007, 
at 1, 2 [hereinafter Weinfurt et al., Developing Model Language]. 
 5.  Kevin P. Weinfurt et al., Policies of Academic Medical Centers for Disclosing Financial 
Conflicts of Interest to Potential Research Participants, 81 ACAD. MED. 113, 114 (2006). 
 6.  Id. 
 7.  Id. at 115. 
 8.  Michaela A. Dinan et al., Comparison of Conflict of Interest Policies and Reported 
Practices in Academic Medical Centers in the United States, 13 ACCOUNTABILITY RES. 325, 328 
(2006). 
 9.  Id. at 333 tbl.4. 
 10.  Id. at 340. 
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B. Stakeholder Input 
Given their relevant interests in COIs in research, we sought data from 
three stakeholder groups: 1) potential research participants; 2) institutional 
officials and investigators; and 3) study coordinators. 
First, we conducted a series of focus groups with potential research 
subjects.11 In these focus groups “we found that many participants want to 
know about financial interests in research, whether or not they report that 
such knowledge would affect their decision to participate. However, we 
documented great variability in participants’ desire and aptitude to 
understand the nature and implications of financial interests in clinical 
research.”12 In addition, in contrast to most commentators on COI, some 
participants thought that financial interests in research might be beneficial.13 
Second, we conducted interviews with selected IRB and COIC officials 
and investigators from academic medical centers, independent hospitals, 
and non-affiliated research entities.14 The interviewees revealed a variety of 
approaches to disclosing financial interests in research as well as differing 
views on what is appropriate in this regard.15 
Third, we surveyed study coordinators who are often charged with 
actually disclosing financial interests to potential research participants.16 
Based on the results, we concluded “that making information about 
financial interests in research readily available to clinical research 
coordinators, as well as providing education and training, would facilitate 
the disclosure of financial interests to potential research participants during 
the informed consent process.”17 
C. Model Disclosure Language and Measuring Trust 
Using a multi-staged process, we developed model disclosure language 
that might be used to describe a variety of financial interests to potential 
research participants.18 In crafting this language, we relied upon existing 
 
 11.  Kevin P. Weinfurt et al., Views of Potential Research Participants on Financial 
Conflicts of Interest: Barriers and Opportunities for Effective Disclosure, 21 J. GEN. INTERNAL 
MED. 901, 901 (2006). 
 12.  Id. at 904. 
 13.  Id. at 903. 
 14.  Kevin P. Weinfurt et al., Disclosing Conflicts of Interest in Clinical Research: Views of 
Institutional Review Boards, Conflict of Interest Committees, and Investigators, 34 J.L. MED. & 
ETHICS 581, 582 (2006) [hereinafter Weinfurt et al., Disclosing Conflicts of Interest]. 
 15.  Id. at 583, 584 tbl.1. 
 16.  Joëlle Y. Friedman et al., Perspectives of Clinical Research Coordinators on 
Disclosing Financial Conflicts of Interest to Potential Research Participants, 4 CLINICAL TRIALS 
272, 273 (2007). 
 17.  Id. at 278. 
 18.  Weinfurt et al., Developing Model Language, supra note 4, at 3. 
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literature, expert review, reactions to draft language during focus groups 
with potential research participants, and cognitive pre-testing with potential 
research participants.19 
As mentioned above, based on the uncertainties that disclosure of 
financial interests in research might have on trust, we wanted to be able to 
accurately measure this important outcome. Since there was no readily 
available measure of trust in medical researchers, we developed and tested 
appropriate scales.20 
D. Effects of Disclosure 
Using the empirically-derived model language, we tested the effects of 
disclosure in two separate studies. The first involved an internet-based survey 
of patients with asthma or diabetes.21 Participants were given a description 
of a hypothetical study of a drug aimed at improving their disease.22 All of 
the information about the studies was identical, except that participants were 
randomly assigned to one of five types of financial interest disclosures.23 In 
most cases, financial interests had no significant differences on willingness 
to participate in the research and trust.24 However, “[r]espondents 
consistently viewed a researcher owning equity less favorably than a 
researcher receiving per capita payments.”25 
Although the internet-based study provided powerful data because of its 
size, it did not have great verisimilitude to actual clinical research practices. 
Therefore, we conducted a phone-based study involving cardiology 
patients.26 In this study, patients received a letter from their cardiologist 
asking if they would be willing to participate in our survey.27 Interested 
patients contacted our research team and were then sent a consent 
document for a hypothetical study involving a medication to improve 
cardiac disease.28 Similar to the internet study, all information about the 
 
 19.  Id. at 2 tbl.1. 
 20.  See Mark A. Hall et al., Measuring Trust in Medical Researchers, 44 MED. CARE 
1048, 1050-51 (2006). 
 21.  Kevin P. Weinfurt et al., Effects of Disclosing Financial Interests on Attitudes Toward 
Clinical Research, 23 J. GEN. INTERNAL MED. 860, 860-61, 865 (2008) [hereinafter Weinfurt 
et al., Effects of Disclosing on Attitudes]. 
 22.  Id. at 861. 
 23.  Id. 
 24.  Id. at 862, 865. 
 25.  Id. at 863. 
 26.  Kevin P. Weinfurt et al., Effects of Disclosing Financial Interests on Participation in 
Medical Research: A Randomized Vignette Trial, 156 AM. HEART J. 689, 689 (2008) 
[hereinafter Weinfurt et al., Effects of Disclosing on Participation]. 
 27.  Id. 
 28.  Id. 
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hypothetical study was the same except that participants were randomly 
assigned to one of three disclosure conditions (per capita payments, equity 
interest, or no disclosure).29 After the patient had received the material, the 
research assistant would review the consent document with them over the 
phone and ask about their willingness to participate in the hypothetical trial 
and measure trust.30 The results were remarkably consistent with those of the 
internet study.31 
E. Goals of Disclosure 
In aggregate, the data we accumulated suggested that there was a lack 
of clarity about the goals of disclosing financial interests in research and that 
there can be barriers to meeting them. Such goals include: promoting 
informed decision making; respecting participants’ perceived right to know; 
establishing or maintaining trust; minimizing risk of legal liability; deterring 
troubling financial relationships; and protecting participants’ welfare.32 In 
the end, disclosure alone seems to be an incomplete management tool for 
financial interests in research.33 Rather, it is best considered an important 
component of management strategies. 
F. COI Management 
Given the importance of management strategies, COINS conducted 
some preliminary research to begin to describe some of the structural issues 
that may be relevant to COIs and the management approaches being used 
in different settings. Based on a small number of interviews with staff at 
health care organizations across the nation, it became apparent that the 
way investigators are compensated in clinical research settings outside of 
academic medical centers, such as community hospitals, may affect whether 
financial interests indeed pose a conflict.34 In addition, a variety of different 
methods are used to address financial interests in research. A survey of 
institutions that participate in high-profile clinical research confirmed that 
different approaches to oversight are used.35 Finally, since per capita 
 
 29.  Id. at 690. 
 30.  Id. 
 31.  Compare Weinfurt et al., Effects of Disclosing on Participation, supra note 26, at 
691, with Weinfurt et al., Effects of Disclosing on Attitudes, supra note 21, at 862. 
 32.  Kevin P. Weinfurt et al., Disclosure of Financial Relationships to Participants in 
Clinical Research, 361 NEW ENG. J. MED. 916, 917 tbl.1 (2009). 
 33.  See id. at 920. 
 34.  Mark A. Hall et al., Community Hospital Oversight of Clinical Investigators’ Financial 
Relationships, IRB: ETHICS & HUMAN RES., Jan.-Feb. 2009, at 9-10. 
 35.  Kevin P. Weinfurt et al., Oversight of Financial Conflicts of Interest in Commercially 
Sponsored Research in Academic and Nonacademic Settings, 25 J. GEN. INTERNAL MED. 460, 
463 (2010). 
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payments in clinical research are commonplace, we explored some of the 
issues related to assessing the acceptability of particular payments. Clearly, 
more attention should focus on how per capita payments for research are 
determined and used in order to assess more accurately whether they pose 
a COI.36 
III.  BARRIERS TO GATHERING DATA ABOUT COIS 
While the COINS team was able to gather systematic data concerning 
the disclosure of financial interests to potential research participants, barriers 
were encountered with respect to two important related areas: nesting a 
study of different disclosures in the context of actual clinical research and 
assessing non-financial conflicts of interest. 
A. Nesting a Study in an Actual Clinical Trial 
As COINS was being developed, we envisioned conducting a 
randomized study of different approaches to disclosing financial interests in 
the context of an actual clinical trial. This method would be best suited to 
provide strong evidence regarding whether the empirically developed 
disclosure language in COINS performed better than existing language. 
While we had substantial experience nesting trials related to informed 
consent in actual research settings,37 the proposed study proved to be 
especially challenging for a variety of reasons. First, in order to conduct a 
nested study about the disclosure of financial interests in research, we 
needed to identify a large enough study to have statistical power to compare 
different approaches to disclosure. Realistically, this required identifying a 
trial being conducted at several institutions. However, because individual 
IRBs and COICs may use different templates for disclosure,38 it would be 
difficult to make a meaningful comparison. Moreover, the necessity for 
multiple reviews would likely undermine our ability to field the trial. A 
practical and ethically acceptable alternative was to identify a multi-
institutional study that was being overseen by an independent IRB that also 
manages financial interests in research. As it turns out, following a meeting 
with its members, a prominent independent IRB was willing to collaborate 
on a trial, testing its standard disclosure language against the COINS 
empirically derived language. Next, we had to identify a trial in which actual 
financial interests were in play, necessitating that we identify an industry-
sponsored trial. Accordingly, we discussed the possibility of collaborating 
 
 36.  Mark A. Hall et al., Per Capita Payments in Clinical Trials: Reasonable Costs Versus 
Bounty Hunting, 85 ACAD. MED. 1554, 1554-56 (2010). 
 37.  See, e.g., Philip W. Lavori et al., Quality Assurance Questionnaire for Professionals 
Fails to Improve the Quality of Informed Consent, 4 CLINICAL TRIALS 638, 638-39 (2007). 
 38.  Weinfurt et al., Disclosing Conflicts of Interest, supra note 14, at 582, 584 tbl.1. 
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with several different sponsors. Although there was substantial interest in the 
research question, ultimately industry sponsors elected not to collaborate, 
tending to cite their corporate fiduciary obligations. Simply put, even though 
financial interests are part of their work, drawing attention to the issue of 
COI was seen to be risky. Thus, without willing collaborators, we had to 
abandon the possibility of testing alternative disclosure language in the 
context of actual research, relying instead on the hypothetical approaches 
described earlier. 
B. Non-Financial Conflicts of Interest 
Although substantial attention has focused on financial COIs, anecdotal 
evidence suggests that non-financial conflicts may pose substantial risks to 
the integrity of the research enterprise. For instance, James Wilson, who was 
the principal investigator in the trial in which Jesse Gelsinger was enrolled, 
describes such conflicts.39 However, given the lack of systematic data 
regarding the nature of non-financial and their potential relationship to 
research integrity and safety, a subset of the COINS team and others set out 
to explore this issue. In crafting the proposal, the team recognized that 
unlike financial interests that are easily quantified, non-financial conflicts 
would likely be difficult to define and understand. Accordingly, the proposal 
included the use of qualitative methods at the outset, such as using focus 
groups and key-informant interviews, to help develop an online survey. 
Unfortunately, the proposal for this work was not funded. Perhaps this was 
related to the difficulty that can be encountered in getting qualitative 
research funded or that the topic itself was threatening.40 Regardless, this 
important work remains undone. 
IV.  CONCLUDING COMMENTS 
Despite the barriers encountered in obtaining some information about 
COIs in research, it has been possible to build a rich data set concerning 
the disclosure of financial interests to potential research participants. These 
data are well situated to enhance disclosure through informed policies and 
practices. In addition, these data challenge some of our assumptions and 
conceptual understandings about financial interests in research. Future 
research should be directed at examining and testing management 
strategies for financial interests in research as well as exploring 
systematically the nature of non-financial COIs in research. 
 
 39.  James M. Wilson, Lessons Learned from the Gene Therapy Trial for 
Ornithine Transcarbamylase Deficiency, 96 MOLECULAR GENETICS & METABOLISM 151, 152, 
156 (2009). 
 40.  Martha Ann Carey & Janice Swanson, Funding for Qualitative Research, 
13 QUALITATIVE HEALTH RES. 852, 852 (2003).  
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